The Effect of Low-Dose Pravastatin in Metabolic Syndrome for Primary Prevention of Cardiovascular Disease in Japan: A Post hoc Analysis of the MEGA Study

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 17, Issue 2, 2012, Pages 153-158

  Matsushima, Teruhiko ^a   Nakaya, Noriaki ^b   Mizuno, Kyoichi ^c   Ohashi, Yasuo ^d   Teramoto, Tamio ^e   Yokoyama, Shinji ^f   Ichikawa, Shuichi ^g   Ishikura, Norio ^h   Kamiyama, Kimihide ⁱ   Nakamura, Haruo ^j  

^a JISSEN WOMEN'S UNIVERSITY   (Japan)

^b Nakaya Clinic   (Japan)

^c NIPPON MEDICAL SCHOOL   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^g Cardiovasc Hosp of Central Japan   (Japan)

^h Toyama Hospital   (Japan)

ⁱ Kamiyama Internal Clinic   (Japan)

^j Mitsukoshi Health and Welfare Foundation   (Japan)

more..

Author keywords

cardiovascular diseases; cholesterol; metabolic syndrome; prevention

Indexed keywords

HYPOCHOLESTEROLEMIC AGENT; PRAVASTATIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIET THERAPY; DOSE RESPONSE; FEMALE; FOLLOW UP; HUMAN; JAPAN; MALE; METABOLIC SYNDROME X; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; COMBINED MODALITY THERAPY; CORONARY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAPAN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PRAVASTATIN; PRIMARY PREVENTION;

EID: 84867186950     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248411421777     Document Type: Article

References (19)

1. Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study Group. Design and baseline characteristics of a study of primary prevention of coronary events with pravastatin among Japanese with mildly elevated cholesterol levels. Circ J. 2004; 68(9):860-867.
2. Nakamura H Arakawa K Itakura H, et al, for the MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. 2006; 368(9542):1155-1163.
3. Sattar N Gaw A Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003; 108(4):414-419.
4. Deedwania PC. Metabolic syndrome and vascular disease: is nature or nurture leading the new epidemic of cardiovascular disease? Circulation. 2004; 109(1):2-4.
5. Girman CJ Rhodes T Mercuri M, et al. and 4 S Group and AFCAPS/TexCAPS Research Group. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4 S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol. 2004; 93(2):136-141.
6. Jeppesen J Hansen TW Rasmussen S Ibsen H Torp-Pedersen C. Metabolic syndrome, low-density lipoprotein cholesterol, and risk of cardiovascular disease: a population-based study. Atherosclerosis. 2006; 189(2):369-374.
7. Grundy SM Cleeman JI Daniels SR, et al. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005; 112(17):2735-2752.
8. Alberti KG Zimmet P Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome—a new worldwide definition. Lancet. 2005; 366(9491):1059-1062.
9. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Geneva: World Health Organization; 1999.
10. Lorenzo C Williams K Hunt KJ Haffner SM. The National Cholesterol Education Program—Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care. 2007; 30(1):8-13.
11. Okamura T Kokubo Y Watanabe M, et al. A revised definition of the metabolic syndrome predicts coronary artery disease and ischemic stroke after adjusting for low density lipoprotein cholesterol in a 13-year cohort study of Japanese: the Suita Study. Atherosclerosis. 2011; 217(1):201-206.
12. National Cholesterol Education Program. Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP II). Washington, DC: US Department of Health and Human Services; 1993.
13. Tanaka Y Matsuyama Y Ohashi Y; MEGA Study Group. Estimation of treatment effect adjusting for treatment changes using the intensity score method: application to a large primary prevention study for coronary events (MEGA study). Stat Med. 2008; 27(10):1718-1733.
14. World Health Organization, International Association for the Study of Obesity, International Obesity Task Force. The Asia Pacific Perspective: Redefining Obesity and its Treatment. Health Communications Australia Pty Ltd; 2000.
15. Deedwania P Barter P Carmena R, et al. Treating to New Targets Investigators. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet. 2006; 368(9539):919-928.
16. Rosamond W Flegal K Friday G, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007; 115(5);e69-e171.
17. Grundy SM Cleeman JI Bairey Merz CN, et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110(2):227-239.
18. Mosca L Banka CL Benjamin EJ, et al. Expert Panel/Writing Group; American Heart Association; American Academy of Family Physicians; American College of Obstetricians and Gynecologists; American College of Cardiology Foundation; Society of Thoracic Surgeons; American Medical Women's Association; Centers for Disease Control and Prevention; Office of Research on Women's Health; Association of Black Cardiologists; American College of Physicians; World Heart Federation; National Heart, Lung, and Blood Institute; American College of Nurse Practitioners. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation. 2007; 115(11):1481-1501.
19. Hsieh SD Muto T. Metabolic syndrome in Japanese men and women with special reference to the anthropometric criteria for the assessment of obesity: proposal to use the waist-to-height ratio. Prev Med. 2006; 42(2):135-139.